Hongri Pharmaceutical: 2025 Annual Report Summary
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
Securities code: 300026 Securities abbreviation: Hongri Pharmaceutical Announcement number: 2026-016
Tianjin Hongri Pharmaceutical Co., Ltd. 2025 Annual Report Summary
1. Important tips
The summary of this annual report comes from the full text of the annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to the media designated by the China Securities Regulatory Commission to carefully read the full text of the annual report.
All directors have attended the board meeting where this report was considered.
The audit opinion of ShineWing Certified Public Accountants (Special General Partnership) on the company's financial report for this year is: standard unqualified opinion.
Non-standard audit opinion tips
□Applicable Not applicable
The company was not profitable when it went public and is not currently profitable.
□Applicable Not applicable
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital reviewed by the board of directors
Applicable □Not applicable
The company's profit distribution plan reviewed and approved by the board of directors this time is: based on 3,004,154,837 shares, a cash dividend of 0.10 yuan (tax included) will be distributed to all shareholders for every 10 shares, 0 bonus shares (tax included) will be given, and capital reserve funds will be transferred to all shareholders to increase 0 shares for every 10 shares.
Preferred stock profit distribution plan for the reporting period approved by the board of directors
□Applicable Not applicable
2. Basic situation of the company
- Company profile
Stock abbreviation Hongri Pharmaceutical Stock Code 300026 Stock Exchange Shenzhen Stock Exchange
Contact person and contact information Secretary of the Board of Directors Name of securities affairs representative Yang Yi Liang Dan
Office address Building B01, Entrepreneurship Headquarters Base, Wuqing Development Zone, Tianjin Building B01, Entrepreneurship Headquarters Base, Wuqing Development Zone, Tianjin Fax 022-59675226 022-59675226
Phone 022-59623217 022-59623217
Email [email protected] [email protected]
- Introduction to main business or products during the reporting period
The company's business layout can be roughly divided into traditional Chinese medicine formula granules, finished drugs, medical devices, raw materials and excipients, medical and health services and pharmaceutical and device smart supply chains, as follows:
(1) Traditional Chinese medicine formula granules
In terms of traditional Chinese medicine formula granules, we insist on taking the inheritance of traditional Chinese medicine as our responsibility, continue to strengthen the construction of authentic traditional Chinese medicine, and actively carry out cooperation with top domestic scientific research institutes in resource assessment, improved variety selection, ecological planting, standardized harvesting and processing, and the construction of authentic medicinal material quality standard systems. We promote the construction of GMP standardized planting demonstration bases and strictly follow the requirements of the "Good Manufacturing Practice for Traditional Chinese Medicine" to implement the four unified management of "unified sources, unified agricultural resources, unified technology, and unified repurchase"
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
Model, explore the introduction of the Internet of Things monitoring system to conduct real-time monitoring of soil moisture, meteorological data, and medicinal material growth conditions, consolidate raw material supply and quality control, and form internal control quality standards that meet the production of high-quality traditional Chinese medicine formula granules. The production adheres to the purpose of "inheriting the ancient and innovating without departing from the tradition". On the one hand, it cooperates with the Institute of Traditional Chinese Medicine of the Chinese Academy of Chinese Medical Sciences to establish a traditional Chinese medicine processing inheritance base and apply the concept of national intangible cultural heritage in the processing process. On the other hand, it innovatively applies modern equipment to create a modern intelligent manufacturing model of traditional Chinese medicine. Through automated production lines and in accordance with the "Technical Key Points Technical Standards" and "Standard Production Management Practices for Decoction Pieces", the traditional Chinese medicine processing technology is fully integrated into the production process of formula granules, achieving industrial quantification.
Kangrentang's "Full Ingredients®" traditional Chinese medicine formula granules are a dosage form reform that inherits traditional Chinese medicine decoctions. Guided by the "Full Ingredient®" concept and "standard decoction" as the standard, authentic medicinal materials are selected as raw materials. The traditional processing experience is digitally represented and processed through modern industrial equipment. For the decoction pieces, based on the quality and quantity transfer research of the entire process of extraction, concentration, drying and preparation, the "material basis" of the formula granules and the traditional decoction are consistent with the "clinical efficacy", which not only maintains the nature, taste and efficacy of the traditional Chinese medicine decoction pieces, but also greatly facilitates the patient's use. At present, the company has deployed eight production bases across the country in Beijing, Tianjin, Hebei, Hubei, Henan, Chongqing, Gansu, and Shandong, and has established a full-process traceability system from medicinal materials, slices, extraction, preparation, packaging, and sales, realizing the traceability of all varieties of formula granules.
(2) Finished medicine
In terms of finished drugs, the overall approach is to focus on independent innovation and combine imitation and innovation, select targets and varieties, continue to strengthen innovation and clinical capacity building, and promote the application development and market transformation of new technologies, new processes and new products. The company's main finished drugs are traditional Chinese medicines and chemicals.
The company’s finished pharmaceutical products:
Serial number Product name Registration category Scope of application
It is used for warm-heat diseases, with symptoms such as fever, shortness of breath, palpitations, irritability and other syndromes of mutual accumulation of blood stasis and toxins. Suitable for systemic inflammatory response syndrome induced by infection; it can also be used to treat impaired organ function in multiple organ dysfunction syndrome 1 Xuebijing Injection Traditional Chinese Medicine
period. It can be used for severe and critical systemic inflammatory response syndrome or/and multiple organ failure due to novel coronavirus pneumonia.
Low molecular weight heparin calcium injection to treat deep vein thrombosis, used to prevent blood clot formation in extracorporeal circulation of hemodialysis, prevention and surgery 2 chemicals
Ejaculation (Bopuqing) related thrombosis.
Moxifloxacin Hydrochloride is a chemical medicine for adults (≥18 years old) with upper and lower respiratory tract infections, such as acute bacterial sinusitis and chronic bronchitis.
3 Sodium Injection (Angol Acute exacerbations of angitis, community-acquired pneumonia; and complex and uncomplicated skin and soft tissue infections; complex
Thailand) Abdominal infection.
Prevention of venous thromboembolic disease (prevention of blood clots in the veins), especially those associated with orthopedic or general surgery. For the treatment of deep vein thrombosis that has formed, with or without pulmonary embolism, the clinical symptoms are not serious, excluding pulmonary embolism that requires surgery or thrombolytic agent treatment. Treat unstable angina pectoris and non-Q wave (Bopulin) myocardial infarction, combined with aspirin. Used in hemodialysis extracorporeal circulation to prevent thrombosis. For the treatment of acute ST-segment elevation myocardial infarction, combined with thrombolytic agents or simultaneously with percutaneous coronary intervention (PCI).
Nadroparin Calcium Injection is used in surgical procedures to prevent venous thromboembolism in situations of moderate or high risk of venous thrombosis. Chemical Drug IV
5 diseases. Treat deep vein thrombosis that has developed. Combined with aspirin for unstable angina and non-Q wave (Bopuai) type
Treatment of acute myocardial infarction. Prevention of blood clot formation in extracorporeal circulation during hemodialysis.
fasudil hydrochloride injection
- Chemical drugs to improve and prevent cerebral vasospasm and subsequent cerebral ischemia symptoms after subarachnoid hemorrhage surgery. Liquid (Sichuan Wei)
Ketorolac Tromethamine Injection Original Chemical Drug
7 Indicated for the short-term treatment of moderate acute pain in adults requiring opioid-level analgesia, often for postoperative analgesia. Cumshot (Boshul) Category 6
Ibandronate Sodium Injection Original chemical drug This product is used to treat postmenopausal osteoporosis; used to treat bone pain caused by osteolytic bone metastasis of malignant tumors; (Gutaiwei) Category 6: Used to treat hypercalcemia caused by malignant tumors with or without bone metastasis.
Qingfei Sanjie Pill (Yi) Qingfei Sanjie Pill, activates blood circulation and relieves pain, detoxifies and resolves phlegm. It is used for lung cancer with Qi and Yin deficiency and phlegm, heat and blood stasis. It can also be used as a traditional Chinese medicine for lung 9.
Novo) adjuvant drug for cancer surgery, radiotherapy and chemotherapy.
It clears away heat and detoxifies, dissipates blood stasis and relieves pain. It is used for gastric cancer, esophageal cancer, cardia cancer, and Zhi 10 Kangaiping Pills (Hengtong) Chinese medicine
Gastrointestinal tumors such as intestinal cancer.
(3) Medical equipment
In terms of medical devices, the company's wholly-owned subsidiary Chaosi Electronics mainly focuses on electronic medical device business, including blood oxygen series, home health and primary care and other new single-parameter or multi-parameter electronic medical products and services, covering blood oxygen, ECG, blood pressure, fetal heart rate monitor, body temperature, multi-parameter monitoring, health examination, all-in-one machine, intelligent oxygen concentrator, portable oxygen concentrator and other products. At the same time, the company also gives full play to its advantages in many monitoring technologies such as blood oxygen, blood pressure, and respiratory rate, as well as intelligent, portable, and wearable technologies, and provides professional guidance for home health care and chronic disease management through specialized disease care. It is committed to meeting the medical care and health management needs of people of different age groups through diversified product lines.
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
The company's holding subsidiary Wenhe Medical Devices is mainly engaged in the research and development, production and sales of medical devices related to medical polymer consumables, and has gradually expanded the development and promotion of food products based on the same source of medicine and food.
(4) Raw and auxiliary materials
In terms of raw materials and auxiliary materials, the company actively promotes product optimization and process improvement through independent innovation + industry-university-research cooperation R&D model, builds an integrated R&D, production and marketing team, and continues to enhance the core competitiveness of the business.
The production and sales of Zhanwang Pharmaceutical, a wholly-owned subsidiary of the company, began in 1950. It is a comprehensive manufacturing enterprise that produces three major series of pharmaceutical excipients, APIs and food additives. It currently has 2 production bases and can complete the production of more than 50 varieties. Adhering to the comprehensive implementation of the quality management system, it has successively passed the US FDA, EU COS certification, Japanese PMDA certification, ISO9001 quality certification, ISO14001 environmental certification and China GMP certification. Its business can cover more than 30 provinces, municipalities and autonomous regions across the country; its overseas business can cover Europe, the United States, Japan, South Korea, India, Southeast Asia, the Middle East, South America and other countries and regions. The company continues to improve the level of intelligent manufacturing and build a full life cycle digital management system from order to delivery, covering R&D, testing, production, logistics and other links. It strengthens efficient collaboration and optimal allocation of resources upstream and downstream of the industrial chain, helping enterprises achieve high-quality development. The company will successfully build a provincial postdoctoral workstation in 2024, further improve the company's R&D system through the establishment of a scientific research talent training platform, enrich the pharmaceutical auxiliary research theory and innovation system, and enhance the academic influence of Zhanzhan Pharmaceutical in the industry.
The company's holding subsidiary, Inori, is a high-tech biopharmaceutical enterprise focusing on the research and development, production, sales and export of heparin, graded low molecular weight heparin APIs and new anti-thrombotic drugs. It is a leading enterprise in domestic heparin extraction technology and has a complete heparin industry chain from pig small intestine processing, mucosal heparin extraction, heparin APIs to graded low molecular weight heparin APIs.
(5) Medical and health services
In terms of medical and health services, with the purpose of creating a digital Chinese medicine service and industry empowerment platform, we adhere to the "full course" diagnosis and treatment development concept, and create a closed-loop ecosystem of "own medicinal material supply chain + own online platform + own offline medical clinics" to continuously refine the diagnosis and treatment experience and improve the accessibility of high-quality traditional Chinese medicine resources.
The company's wholly-owned subsidiary Dongfang Kangsheng is the company's medical and health investment and management platform, specializing in investment and management in the field of traditional Chinese medicine medical and health services. Through the ad hoc online Chinese medicine Internet service platform "Shangyi Mingjia", the offline national physical chain "Shangyi Ming Traditional Chinese Medicine Clinic" and a high-quality product supply system, it creates a three-dimensional traditional Chinese medicine full industry chain service ecosystem and a unified brand image of traditional Chinese medicine medical and health services. At present, the offline "Shangyi Ming Traditional Chinese Medicine Clinic" has covered many provinces and cities such as Beijing, Tianjin, and Sichuan. On the basis of the original pieces and traditional Chinese medicine formula granules, it continues to enrich the content of products and services, innovate application scenarios, and achieve from pre-diagnosis prevention to in-diagnosis treatment, from post-diagnosis recovery to drug distribution, bringing more convenience to patients, and continuing to help the transformation of medical services into health services and traditional Chinese medicine life.
(6) Pharmaceutical and device smart supply chain
In terms of pharmaceutical and device smart supply chain, information technology and automation equipment are applied to create a pharmaceutical and device supply chain and logistics extension service platform to realize digital management of the entire process of procurement, logistics, and use. Zhengkang Medical Technology, a wholly-owned subsidiary of the company, is a leading supply chain technology company in China. Its main businesses are SPD technology research and development and services, and equipment sales.
- Main accounting data and financial indicators
(1) Main accounting data and financial indicators in the past three years
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□Yes No
Yuan project End of 2025 End of 2024 Increase or decrease at the end of this year compared with the end of the previous year Total assets at the end of 2023 10,392,116,497.80 11,165,116,699.53 -6.92% 11,835,031,507.96 Attributable to shareholders of listed companies
8,516,636,507.69 8,643,891,935.85 -1.47% Net assets of 8,710,063,623.49
Item 2025 2024 Increase or decrease this year compared with the previous year Operating income in 2023 4,941,124,549.57 5,782,766,928.71 -14.55% 6,108,854,649.13 Attributable to shareholders of the listed company
18,495,135.72 21,467,322.65 -13.85% Net profit of 506,631,425.70
Attributable to shareholders of listed companies
21,575,688.86 -7,607,061.84 383.63% 375,550,639.28 excluding non-recurring gains and losses
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
net profit
Cash generated from operating activities
811,341,610.79 852,244,831.66 -4.80% 1,530,094,404.76 Net flow
Basic earnings per share (yuan/
0.01 0.01 0.00% 0.17 shares)
Diluted earnings per share (yuan/
0.01 0.01 0.00% 0.17 shares)
weighted average net asset income
0.22% 0.25% -0.03% 5.97% rate
(2) Main accounting data by quarter
Unit: yuan item First quarter Second quarter Third quarter Fourth quarter operating income 1,392,772,566.61 1,402,195,703.58 1,353,594,654.88 792,561,624.50 Attributable to shareholders of listed companies
60,329,743.62 18,300,275.69 2,132,915.33 -Net profit of 62,267,798.92
Attributable to shareholders of listed companies
Net profit after deducting non-recurring gains and losses 54,859,203.97 14,320,445.85 19,525,146.55 -67,129,107.51
Cash generated from operating activities
103,952,295.10 279,580,706.43 153,303,634.96 274,504,974.30 Net flow
Are there any significant differences between the above financial indicators or their totals and the relevant financial indicators disclosed by the company in quarterly reports and semi-annual reports?
□Yes No
- Share capital and shareholders
(1) The number of common shareholders and preferred shareholders whose voting rights have been restored, and the shareholding status of the top 10 shareholders
Unit: annual report of shares holding special
reporting period
Report Disclosure Don’t Vote
Voting at the end of the reporting period Before the annual report disclosure date
One share of the day before
Ordinary rights are restored at the end of the month Voting rights are restored at the end of one month
93,824 At the end of the month 91,988 0 0 shareholders of 0 shareholders of preferred shares of the total number of preferred shareholders of
Total number of common shares
Total number of shareholders
total shareholders (e.g.
total
number (yes)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Name of shareholder, nature of the shareholder, shareholding ratio, conditions for holding sales restrictions, pledge, mark or freeze status
Number of shares held
Weigh Quality Example Number of shares Share status Quantity Chengdu Xing
Urban investment state-owned law
22.24% 667,997,417.00 0.00 Pledge 243,820,162.00 Group owner
Ltd.
within the territory of
Yao Xiaoqing 10.00% 300,405,728.00 0.00 Not applicable 0.00 Random person
within the territory of
Li Zhuo 4.40% 132,262,401.00 0.00 Not applicable 0.00
Ranren
Tianjin University Domestic non-profit 2.26% 68,036,432.00 0.00 Pledge 67,080,000.00
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
Pass investment state-owned law
Someone in the group has frozen 68,036,432.00 Co., Ltd.
within the territory of
Yan Yan 1.13% 33,829,100.00 0.00 Not applicable 0.00 Random person
within the territory of
Wu Guangning 1.12% 33,584,715.00 0.00 Not applicable 0.00 Random person
within the territory of
Yan Yaopeng 0.67% 20,110,000.00 0.00 Not applicable 0.00
Ranren
China Merchants Bank
bank shares
limited company
Si-Nan
Fang Zhongzheng
1000 payment Others 0.64% 19,247,996.00 0.00 Not applicable 0.00 Easy-to-open
open finger
Digital securities
investment base
gold
Hong Kong
Central clearing and settlement overseas law
0.59% 17,844,147.00 0.00 Not applicable 0.00 Limited public person
Division
Zhaoqing City
Honglifang Domestic and non-local
Real Estate Development State-owned Law 0.57% 17,031,450.00 0.00 Not applicable 0.00 Development Co., Ltd. Person
company
The above-mentioned shareholder related relationships
The company does not know whether there is any related relationship or concerted action relationship between the above shareholders. or description of concerted action
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable Not applicable
Whether the company has differential voting rights arrangements
□Applicable Not applicable
(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
The company has no preference shareholders’ shareholdings during the reporting period.
(3) Disclose the property rights and control relationship between the company and the actual controller in the form of a block diagram
Summary of the 2025 Annual Report of Tianjin Hongri Pharmaceutical Co., Ltd.
- Bonds existing on the date of approval of the annual report □Applicable Not applicable
3. Important matters
None.